Sickle Cell Disease
Tanzania has one of the world's highest rates of sickle cell disease — approximately 11,000 children are born with it each year. Early newborn screening and hydroxyurea prevent serious complications.
Always confirm diagnosis and treatment with a qualified health professional.
Compiled from public health references including the CDC, Mayo Clinic, WebMD, the World Health Organization, and the Tanzania Ministry of Health.
Overview
Sickle cell disease (SCD) is an inherited blood disorder where red blood cells are abnormally shaped, causing blockages in blood vessels ("crises"), anaemia, organ damage, and increased risk of infections. Tanzania's carrier rate is 13–14% — among the highest globally. Children born in Tanzania can access free SCD screening and treatment at referral hospitals.
Common Symptoms
- Episodes of severe pain ("sickle cell crisis") — hands, feet, chest, back
- Anaemia: fatigue, pale skin, jaundice
- Swollen hands and feet in infants (dactylitis)
- Frequent infections
- Delayed growth
- Stroke (especially in children)
- Acute chest syndrome (chest pain + fever + breathing difficulty)
Treatment
- Hydroxyurea: Reduces frequency of crises and hospital admissions — available at referral hospitals
- Daily penicillin V: Prophylaxis against infections (from birth to age 5)
- Folic acid: Daily supplement
- Pain crisis management: Fluids, pain relief (ibuprofen/morphine), oxygen
- Blood transfusion: For severe anaemia or stroke prevention
- Bone marrow transplant: Potentially curative but not widely available in Tanzania
Prevention
- Genetic counselling: Couples should test for sickle cell trait before having children
- Newborn screening: Available at Muhimbili and select regional hospitals — early diagnosis prevents complications
- Vaccinations: Pneumococcal, meningococcal, Hib, flu — critical for SCD patients
- Daily penicillin from birth protects against life-threatening infections
Cost & NHIF Coverage
Public facilities: Screening (haemoglobin electrophoresis) and folic acid supplementation at subsidised cost; specialist sickle-cell clinics exist at major referral hospitals.
NHIF: Covers ongoing consultations, blood transfusion, and pain-crisis management at accredited facilities as a chronic condition.
Private facilities: Screening test TZS 25,000–50,000; a pain-crisis admission with transfusion can run TZS 150,000–500,000+ depending on units of blood required.
Estimated ranges — actual cost varies by facility. Confirm with reception and check your insurer's coverage before treatment.
Where to Get Care
Confirm with reception that the facility treats this condition and that your insurer is accepted before visiting.